Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole 40 mg once daily for 8 weeks in gastroesophageal reflux disease
2005-003485-42Phase 3Completed
- Sponsor
- Altana Pharma
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pantoprazole in gastroesophageal reflux disease (GERD), sponsored by Altana Pharma. Primary endpoint: Primary treatment response at week 8. Started Feb 2006; status: completed.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2005-003485-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003485-42.